POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER
Clinical trials for POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER explained in plain language.
Never miss a new study
Get alerted when new POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER trials appear
Sign up with your email to follow new studies for POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Custom immune cells target dangerous virus in transplant patients
Disease control Recruiting nowThis early-stage study is testing a new cell therapy for patients who develop an Epstein-Barr virus (EBV) infection after a stem cell transplant. Researchers are using specially engineered immune cells designed to find and attack cells infected with the virus. The main goals are …
Matched conditions: POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER
Phase: PHASE1, PHASE2 • Sponsor: Daihong Liu • Aim: Disease control
Last updated Apr 02, 2026 14:57 UTC
-
Fighting a dangerous virus with a Patient's own immune cells
Disease control Recruiting nowThis early-stage study is testing a new cell therapy for patients who develop a dangerous Epstein-Barr virus (EBV) infection after a stem cell transplant. The main goal is to find a safe dose of specially prepared immune cells designed to fight the virus. Researchers will also ch…
Matched conditions: POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER
Phase: PHASE1, PHASE2 • Sponsor: Daihong Liu • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
New hope for lymphoma patients who have run out of options
Disease control Recruiting nowThis study is testing whether a drug called loncastuximab tesirine can shrink tumors in adults with specific types of B-cell lymphoma that have come back or stopped responding to other treatments. The drug is designed to target cancer cells directly. Researchers will give the dru…
Matched conditions: POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated Mar 25, 2026 14:07 UTC
-
New hope for transplant patients fighting cancer without harsh chemo
Disease control Recruiting nowThis study is testing whether combining two drugs—polatuzumab vedotin and rituximab—is safe and effective for treating a type of lymphoma that can develop after an organ or stem cell transplant. The goal is to control the cancer while avoiding the severe side effects of tradition…
Matched conditions: POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER
Phase: PHASE1, PHASE2 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Mar 16, 2026 15:25 UTC